K. Francoeur

发表

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

A. LaCasce, M. Davids, D. Fisher, 2017 .

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

M. Davids, D. Fisher, E. Jacobsen, 2019, The Lancet. Haematology.

Vaccination with DC/tumor fusion cells results in cellular and humoral anti-tumor immune responses in patients with multiple myeloma DC/myeloma fusion vaccine induces immune responses

N. Munshi, P. Richardson, D. Kufe, 2017 .

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

S. Tyekucheva, P. Armand, M. Davids, 2020, Leukemia.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

A. Alencar, A. LaCasce, S. Tyekucheva, 2019, The Lancet. Haematology.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia*

A. LaCasce, S. Fernandes, M. Davids, 2018, Leukemia & lymphoma.

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

N. Munshi, P. Richardson, D. Kufe, 2011, Blood.

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

M. Davids, D. Fisher, C. Jacobson, 2016 .

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, M. Davids, D. Fisher, 2017 .

UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL

M. Davids, D. Fisher, C. Jacobson, 2017 .

Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL

M. Davids, D. Fisher, Jennifer R. Brown, 2015 .

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

S. Tyekucheva, M. Davids, D. Fisher, 2020 .

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

M. Davids, D. Fisher, C. Jacobson, 2016 .

INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE‐ADJUSTED R‐EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC‐043)

S. Tyekucheva, M. Davids, D. Fisher, 2019, Hematological Oncology.